Abstract

To estimate the economic burden of CKD-T2D from a social perspective[1] in two scenarios: the standard of care (SoC) used in Colombia and the standard of care plus Finerenone, a nonsteroidal, selective antagonist of the mineralocorticoid receptor studied for the management of adults with CKD (eGFR ≥ 25mL/min with albuminuria) and T2D.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.